A novel cell-cycle-regulated interaction of the Bloom syndrome helicase BLM with Mcm6 controls replication-linked processes von Shastri, Vivek M, Subramanian, Veena, Schmidt, Kristina H

Volltext

A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials von Gbadamosi, Mohammed O., Shastri, Vivek M., Elsayed, Abdelrahman H., Ries, Rhonda, Olabige, Oluwaseyi, Nguyen, Nam H. K., De Jesus, Angelica, Wang, Yi-Cheng, Dang, Alice, Hirsch, Betsy A., Alonzo, Todd A., Gamis, Alan, Meshinchi, Soheil, Lamba, Jatinder K.

Volltext

Novel CD33 antibodies unravel localization, biology and therapeutic implications of CD33 isoforms von Gbadamosi, Mohammed O, Shastri, Vivek M, Hylkema, Tiffany, Papageorgiou, Ioannis, Pardo, Laura, Cogle, Christopher R, Doty, Andria, Loken, Michael R, Meshinchi, Soheil, Lamba, Jatinder K

Volltext

Cellular defects caused by hypomorphic variants of the Bloom syndrome helicase gene BLM von Shastri, Vivek M., Schmidt, Kristina H.

Volltext

Splicing Polymorphism rs12459419 Modulates Antibody-Bound Internalization of CD33 Isoforms von Shastri, Vivek M., Gbadamosi, Mohammed O., Lamba, Jatinder K.

Volltext

Abstract P18: Splicing polymorphism rs12459419 modulates antibody-bound internalization of CD33 isoforms von Shastri, Vivek M, Lamba, Jatinder K

Volltext

Unraveling Subcellular Localization of CD33 Splicing Polymorphism Variant von Shastri, Vivek M., Hylkema, Tiffany A., Gbadamosi, Mohammed O, Meshinchi, Soheil, Lamba, Jatinder K.

Volltext

The rs35112940 CD33 Polymorphism Reduces CD33 Internalization and Efficacy of CD33-Directed Gemtuzumab Ozogamicin von Gbadamosi, Mohammed O, Shastri, Vivek M., Meshinchi, Soheil, Lamba, Jatinder K.

Volltext

Abstract P166: The rs35112940 CD33 polymorphism reduces CD33 internalization and efficacy of CD33-directed gemtuzumab ozogamicin von Gbadamosi, Mohammed O., Shastri, Vivek M., Meshinchi, Soheil, Lamba, Jatinder K.

Volltext

ACS10- Cytarabine Pharmacogenomics Score Impacts Survival in Pediatric AML Patients Treated on AAML1031 Trial and Associates with Outcome Differences in Black AML Patients von Marrero, Richard J, Shastri, Vivek M., Aplenc, Richard, Cooper, Todd, Alonzo, Todd A., Gamis, Alan S, Wang, Jim, Meshinchi, Soheil, Kolb, E. Anders, Lamba, Jatinder K.

Volltext

Pharmacogenomics to Predict Mucositis in Acute Myeloid Leukemia von Ahmed, Jennifer, Becirevic, Leila, Emanuel, Natasha, Lofy, Molly E., Tran, Hanh, Shastri, Vivek M., Lamba, Jatinder K.

Volltext

Pharmacogenomics to Predict Asparaginase Premedication-Related Hypersensitivity in Pediatric and Adolescent Young Adults (AYAs) with Acute Lymphoblastic Leukemia or Lymphoma von Shastri, Vivek M., Ahmed, Jennifer, Spin, Eva, Nunez, Yeniffer, Morales, Sonia, Agrawal, Anurag, Phillips, Christine L, August, Keith J., Guest, Erin M., Apsel Winger, Beth, Aftandilian, Catherine, Huynh, Van Thu, Lamba, Jatinder K.

Volltext

Impact of Cytarabine Pharmacogenomics on Survival of Adolescent and Young Adults with AML and Its Clinical Relevance in Black Patients von Marrero, Richard J, Nicolet, Deedra, Shastri, Vivek M., Mrózek, Krzysztof, Walker, Christopher J., Blum, William, Powell, Bayard L, Kolitz, Jonathan E, Moore, Joseph O, Uy, Geoffrey L, Stock, Wendy, Carroll, Andrew J, Byrd, John C., Eisfeld, Ann-Kathrin, Lamba, Jatinder K.

Volltext

Relapse-Enriched Gene Expression Signature of Prognostic Relevance in Pediatric Acute Myeloid Leukemia von Nittu, Satyavardhan Rao, Marchi, Francisco, Nguyen, Nam, Shastri, Vivek M., Cao, Xueyuan, Ribeiro, Raul C., Rubnitz, Jeffrey E., Gamis, Alan S, Kolb, E. Anders, Aplenc, Richard, Klco, Jeffery, Pounds, Stanley, Alonzo, Todd A., Meshinchi, Soheil, Lamba, Jatinder K.

Volltext

Pharmacogenomics of Fludarabine in Pediatric HCT Recipients: Preliminary Results von Nguyen, Nam H.K., Shastri, Vivek M., Lu, Ying, Winger, Beth Apsel, Long-Boyle, Janel R., Horn, Biljana N., Lamba, Jatinder K.

Volltext

Pharmacogenomic Single Nucleotide Polymorphism (SNP) Variants As Predictors of Toxicity Phenotypes in the Treatment of Acute Childhood Leukemia von Kashif, Reema, Larkin, Trisha, Elsayed, Abdelrahman H, Nguyen, Nam H.K., Emanuel, Natasha, Shastri, Vivek M., Rafiee, Roya, Mangrola, Karna, Horn, Biljana N., Lamba, Jatinder K.

Volltext

A Polygenic DNA Damage Repair Pharmacogenomics (DDR_PGx8) Score Predicts GO Response in AML von Shastri, Vivek M., Chauhan, Lata, Alonzo, Todd A., Wang, Yi-Cheng, Aplenc, Richard, Hirsch, Betsy A, Gamis, Alan S., Meshinchi, Soheil, Lamba, Jatinder K.

Volltext

Abstract 1921: The DDB2 intronic variation rs830083 is a strong predictor of gemtuzumab ozogamicin response in AML patients: A calicheamicin pathway-directed analysis from the COG-... von Shastri, Vivek M., Chauhan, Lata, Alonzo, Todd A., Wang, Yi-Cheng, Aplenc, Richard, Hirsch, Betsy A., Gamis, Alan S., Meshinchi, Soheil, Lamba, Jatinder K.

Volltext

Genetic variation in DNA damage response pathway and response to Gemtuzumab Ozogamicin in pediatric AML: a report from the Children's Oncology Group von Shastri, Vivek M, Chauhan, Lata, Gbadamosi, Mohammed, Alonzo, Todd A, Wang, Yi-Cheng, Aplenc, Richard, Hirsch, Betsy A, Kolb, Edward A, Gamis, Alan S, Meshinchi, Soheil, Lamba, Jatinder K

Volltext

Delta variant SARS-CoV-2 infections in pediatric cases during the second wave in India von Yadav, Pragya D., Kumar, Gunjan, Mukherjee, Aparna, Nyayanit, Dimpal A., Shete, Anita M., Sahay, Rima R., Kumar, Abhinendra, Majumdar, Triparna, Patil, Savita, Pandit, Priyanka, Joshi, Yash, Dudhmal, Manisha, Panda, Samiran, Sharma, Lokesh Kumar, Yadav Ml, Kala, Shastri, Jayanthi, Gangwar, Mayank, Munivenkattapa, Ashok, Potdar, Varsha, Nagamani, K., Goyal, Kapil, Gadepalli, Ravisekhar, Thomas, Maria, Shukla, Suruchi, Nagraj, P., Gupta, Vivek, Dalela, Gaurav, Umar, Nawaz, Patel, Sweety M.

Volltext